Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Operating Leases (2019 - 2025)

Wave Life Sciences (WVE) has disclosed Operating Leases for 7 consecutive years, with $9.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Leases fell 47.06% year-over-year to $9.4 million, compared with a TTM value of $9.4 million through Dec 2025, down 47.06%, and an annual FY2025 reading of $9.4 million, down 47.06% over the prior year.
  • Operating Leases was $9.4 million for Q4 2025 at Wave Life Sciences, down from $11.4 million in the prior quarter.
  • Across five years, Operating Leases topped out at $33.7 million in Q3 2022 and bottomed at $9.4 million in Q4 2025.
  • Average Operating Leases over 5 years is $22.1 million, with a median of $23.6 million recorded in 2021.
  • The sharpest move saw Operating Leases crashed 49.04% in 2022, then surged 140.62% in 2023.
  • Year by year, Operating Leases stood at $25.0 million in 2021, then rose by 28.7% to $32.1 million in 2022, then dropped by 20.9% to $25.4 million in 2023, then crashed by 30.07% to $17.8 million in 2024, then crashed by 47.06% to $9.4 million in 2025.
  • Business Quant data shows Operating Leases for WVE at $9.4 million in Q4 2025, $11.4 million in Q3 2025, and $13.6 million in Q2 2025.